eptinezumab is in phase iii trials. its maker plans to submit an application with the fda later this year. it is for chronic migraine prevention.
.
.
.
now the country may face a fine of millions of euros after its dereliction was referred to the european court of justice (ecj), the guardian reports.
.
.
(open access) shows that athletes of the mind � chess grandmasters � show the same longevity advantage as athletes of the body.
.